WO2012049431A3 - Use of an anti-cd20 antibody for treating primary cerebral lymphoma - Google Patents

Use of an anti-cd20 antibody for treating primary cerebral lymphoma Download PDF

Info

Publication number
WO2012049431A3
WO2012049431A3 PCT/FR2011/052392 FR2011052392W WO2012049431A3 WO 2012049431 A3 WO2012049431 A3 WO 2012049431A3 FR 2011052392 W FR2011052392 W FR 2011052392W WO 2012049431 A3 WO2012049431 A3 WO 2012049431A3
Authority
WO
WIPO (PCT)
Prior art keywords
primary cerebral
cerebral lymphoma
antibody
present
treating primary
Prior art date
Application number
PCT/FR2011/052392
Other languages
French (fr)
Other versions
WO2012049431A2 (en
Inventor
Rémi Urbain
Sylvain Fisson
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Publication of WO2012049431A2 publication Critical patent/WO2012049431A2/en
Publication of WO2012049431A3 publication Critical patent/WO2012049431A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a monoclonal antibody directed against the CD20 antigen, the variable region of each of the light chains of which is encoded by the murine nucleic acid sequence SEQ ID NO: 1, the variable region of each of the heavy chains of which is encoded by the murine nucleic acid sequence SEQ ID NO: 2, and the constant regions of the light chains and of the heavy chains of which come from a nonmurine species, for use thereof in the treatment of primary cerebral lymphoma. The present invention also relates to an antibody directed against an antigen present at the surface of primary cerebral lymphoma cells, for use thereof via intrathecal administration in the treatment of primary cerebral lymphoma.
PCT/FR2011/052392 2010-10-14 2011-10-13 Use of an anti-cd20 antibody for treating primary cerebral lymphoma WO2012049431A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1058368 2010-10-14
FR1058368A FR2966043A1 (en) 2010-10-14 2010-10-14 USE OF ANTI-CD20 ANTIBODY FOR THE TREATMENT OF PRIMITIVE CEREBRAL LYMPHOMA

Publications (2)

Publication Number Publication Date
WO2012049431A2 WO2012049431A2 (en) 2012-04-19
WO2012049431A3 true WO2012049431A3 (en) 2012-10-26

Family

ID=43866702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2011/052392 WO2012049431A2 (en) 2010-10-14 2011-10-13 Use of an anti-cd20 antibody for treating primary cerebral lymphoma

Country Status (3)

Country Link
AR (1) AR083439A1 (en)
FR (1) FR2966043A1 (en)
WO (1) WO2012049431A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2879204A1 (en) * 2004-12-15 2006-06-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
US20060246004A1 (en) * 2005-02-07 2006-11-02 Genentech, Inc. Antibody variants and uses thereof
WO2006133148A2 (en) * 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
FR2894982A1 (en) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Preparation of antibodies selective for activating Fc receptors, useful for treatment of tumors and viral or bacterial infections, by replacing specific histidine residues in the Fc region of a monoclonal antibody
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
FR2915398A1 (en) * 2007-04-25 2008-10-31 Lab Francais Du Fractionnement "SET OF MEANS FOR THE TREATMENT OF MALIGNANT PATHOLOGY, AUTOIMMUNE DISEASE OR INFECTIOUS DISEASE"
WO2010076400A1 (en) * 2008-12-30 2010-07-08 Lfb Biotechnologies Use of an anti-cd20 antibody for treating primary intraocular lymphoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4668498B2 (en) 1999-10-19 2011-04-13 協和発酵キリン株式会社 Method for producing polypeptide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2879204A1 (en) * 2004-12-15 2006-06-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
US20060246004A1 (en) * 2005-02-07 2006-11-02 Genentech, Inc. Antibody variants and uses thereof
WO2006133148A2 (en) * 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
FR2894982A1 (en) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Preparation of antibodies selective for activating Fc receptors, useful for treatment of tumors and viral or bacterial infections, by replacing specific histidine residues in the Fc region of a monoclonal antibody
FR2915398A1 (en) * 2007-04-25 2008-10-31 Lab Francais Du Fractionnement "SET OF MEANS FOR THE TREATMENT OF MALIGNANT PATHOLOGY, AUTOIMMUNE DISEASE OR INFECTIOUS DISEASE"
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
WO2010076400A1 (en) * 2008-12-30 2010-07-08 Lfb Biotechnologies Use of an anti-cd20 antibody for treating primary intraocular lymphoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABES RIAD ET AL: "Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 116, no. 2, 12 August 2010 (2010-08-12), pages 926 - 934, XP009147509, ISSN: 0006-4971, [retrieved on 20100503], DOI: DOI:10.1182/BLOOD-2009-10-248609 *
FANALE MICHELLE A ET AL: "Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 67, no. 3, 1 January 2007 (2007-01-01), pages 333 - 350, XP009101539, ISSN: 0012-6667, DOI: DOI:10.2165/00003495-200767030-00002 *
GIOVANNI ANTONINI ET AL: "Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma", JOURNAL OF NEURO-ONCOLOGY, KLUWER ACADEMIC PUBLISHERS, BO, vol. 81, no. 2, 26 August 2006 (2006-08-26), pages 197 - 199, XP019467373, ISSN: 1573-7373, DOI: DOI:10.1007/S11060-006-9217-Y *

Also Published As

Publication number Publication date
AR083439A1 (en) 2013-02-27
WO2012049431A2 (en) 2012-04-19
FR2966043A1 (en) 2012-04-20

Similar Documents

Publication Publication Date Title
WO2010076400A8 (en) Use of an anti-cd20 antibody for treating primary intraocular lymphoma
EA035160B9 (en) Anti-st2 antibodies and use thereof
NZ705848A (en) Anti-cd38 antibodies
MX2020001873A (en) Binding agents.
EA201890162A1 (en) ANTIBODIES TO CD40 WITH ENHANCED AGONISTIC ACTIVITY
EA201890175A1 (en) ANTIBODIES TO CD40
WO2006064121A3 (en) Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations
MX2019007848A (en) Anti-pd-1 antibodies and uses thereof.
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ611468A (en) Humanized antibodies to liv-1 and use of same to treat cancer
NZ610734A (en) Human antibodies to the glucagon receptor
EA201891925A1 (en) ANTIBODIES TO CD40 WITH STRENGTHENED AGONISTIC ACTIVITY
TN2012000555A1 (en) Antibodies to human gdf8
NZ598063A (en) Gram-positive bacteria specific binding compounds
NZ614125A (en) Cea antibodies
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
MX2018009498A (en) Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes.
WO2012068540A3 (en) Neutralizing anti-ccl20 antibodies
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
NZ594682A (en) Fully human antibodies specific to cadm1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11832115

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11832115

Country of ref document: EP

Kind code of ref document: A2